Edding Genor Group Holdings Ltd. engages in the development and commercialization of oncology and autoimmune drugs. The company employs 1,545 full-time employees The company went IPO on 2020-10-07. The Company’s main business is engaged in the discovery, development and commercialization of biopharmaceutical products for human use. The Company’s product pipelines include Lerociclib (GB491), GB261, GB263T, Infliximab (GB242), Coprelotamab (GB221), GB223, Rituximab (GB241) and other products, covering disease fields such as breast cancer, lung cancer, gastrointestinal tumors, and blood tumors. The firm mainly conducts its businesses in the domestic market.